Merck KGaA Boosts Diversification Effort With $7 Billion Acquisition Of Millipore
This article was originally published in The Pink Sheet Daily
Merck KGaA strengthens its pharmaceutical services business with a $107-a-share agreement to buy the US life sciences company Millipore.
You may also be interested in...
Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: Medical device financings raised $609 million, the lowest since 2009's opening quarter brought in $521 million. More than half of Q1's total dollars came from VC funding with late-stage rounds garning the most. The largest financing was Mindray Medical's $151 million follow-on offering. Seven private companies involved with biomaterials companies were heavy hitters, together accounting for 14% of Q1 2010's financing dollars. There wasn't much M&A activity with just 10 deals pulling in $1.4 billion, the lowest quarter since Q2 2009's $794 million take, however, four transactions did top the $100 million mark. Financing for the in vitro diagnostics/research segment was also disappointing: only $144 million was raised, less than half of what these industries pulled in during Q4 2009 and was way down from 2009's $522 million opening quarter. Conversely, M&A activity was up. Even without counting Merck KGAA's massive $7 billion-plus takeover of research tools company Millipore Corp., the aggregate of the quarter's seven other M&A's ($729 million) still well exceeded that of the closing quarter of 2009, thanks to multiple deals reaching $100 million or more.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.